Vivo Surgical Honored with the Esteemed WIPO-IPOS IP for Innovation Award

Vivo Surgical, a pioneering medical device company based in Singapore, has become the first start-up to win the prestigious WIPO-IPOS IP for Innovation Award for 2022.

Now in its 10th year, this award celebrates Singaporean companies that have achieved outstanding growth through the successful application of intangible assets and intellectual property. Over 40 organizations have received this highly regarded accolade since its inception, with this year’s criteria centered around adaptable and resilient companies emerging through recent global challenges.

Vivo Surgical’s products and pipeline comprise innovative medical devices that enhance how surgeries are performed worldwide. The company is currently developing the world’s first disposable robot for natural orifice transluminal endoscopic surgeries (NOTES), and a portable endoscopic diagnostic device – ENLYT™ – with technologies that will eventually be incorporated into the robot’s final design. These solutions will complement the company’s existing CE-certified KLARO™ in vivo lighting device, which is designed to address inadequate illumination in operating theatres, providing a clearer view of surgical cavities. The company is now working with several renowned hospitals across the US, Europe and Asia, and its devices are distributed in multiple international territories.

Dr. Kevin Koh, CEO of Vivo Surgical, commented:

“In just four-and-a-half years, we have built a company that focuses on addressing clinical needs with cutting-edge technologies. Being recognized with this award is a huge moment, not only for the team at Vivo Surgical, but also for all the patients our products help around the world. We hope that this achievement demonstrates how a young company like ours can punch above its weight on the world stage, and inspire other start-ups to do the same.”

Hot this week

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution